
|Videos|December 1, 2021
Clinical Implications of JAK Inhibitors
Author(s)Mary Scoviak, Managing Editor
In this video interview, James Q Del Rosso, DO, tackles the clinical impact of JAK Inhibitors and how to deal with patient concern.
Advertisement
James Q Del Rosso, DO, Research Director of JDR Dermatology Research in Las Vegas, Nevada and Senior Vice President of Clinical Research and Strategic Development at Advanced Dermatology & Cosmetic Surgery in Maitland, Florida, sits down with Dermatology Times® to discuss the practical challenges and opportunities available as JAK inhibitors move from pipeline to clinical practice.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















